Praluent Cost in Missouri 2026: Prices, Insurance, Medicaid, and Compounding Options

What Is Alirocumab and Why Does It Matter for Missouri Patients?

Alirocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, alirocumab increases the number of active LDL receptors and lowers circulating LDL-cholesterol by 46 to 61 percent compared with placebo across the ODYSSEY trial program. Missouri has roughly 1.2 million adults with cardiovascular disease, according to CDC state-level prevalence data, meaning access to PCSK9 inhibitors is a population-level concern, not just an individual one.

The FDA approved alirocumab in July 2015 as an adjunct to diet and maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering. The full prescribing information is available on the FDA's accessdata portal. [1] The standard starting dose is 75 mg subcutaneously every two weeks, with titration to 150 mg every two weeks if LDL-C response is inadequate after eight to twelve weeks. [1]

The ACC/AHA 2019 Guideline on the Primary Prevention of Cardiovascular Disease states that PCSK9 inhibitors are reasonable for patients with clinical ASCVD whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe therapy. [2] That guideline threshold directly determines which Missouri patients qualify for insurance prior authorization in 2026.

LDL lowering at this magnitude translates to hard outcomes. The ODYSSEY OUTCOMES trial (N=18,924) compared alirocumab 75 to 150 mg every two weeks against placebo in patients with recent acute coronary syndrome on high-intensity statin therapy and showed a 15 percent relative reduction in the composite of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina (HR 0.85 to 95% CI 0.78 to 0.93, P<0.001). [3] That reduction translated to an absolute risk difference of 1.6 percent over a median 2.8 years of follow-up. [3]

Familial hypercholesterolemia affects approximately 1 in 250 individuals in the general population, per a 2020 European Heart Journal review. [4] Missouri's population of roughly 6.2 million implies approximately 24,800 residents with HeFH, many of whom are either undiagnosed or not receiving guideline-directed therapy. [4]

What Does Praluent Actually Cost in Missouri in 2026?

The manufacturer list price for Praluent sits at approximately $580 per month in 2026 across Missouri retail pharmacies. That figure represents the wholesale acquisition cost and is what uninsured patients pay without assistance programs.

Cash-pay prices at major Missouri pharmacy chains, including Walgreens, CVS, and Walmart locations in St. Louis, Kansas City, and Springfield, track closely to that list figure because alirocumab has no generic equivalent approved by the FDA as of mid-2025. The FDA's Orange Book confirms no approved generic alirocumab. [5] Without a generic competitor, downward pricing pressure from retail substitution does not yet apply.

At $580 per month, annual expenditure reaches $6,960 before any co-pay or deductible. That cost burden is high enough that adherence data from a 2021 JAMA Cardiology analysis of PCSK9 inhibitor claims found only 36 percent of commercially insured patients remained on therapy at 12 months, largely driven by out-of-pocket cost. [6] Missouri patients face the same adherence economics.

The ICER (Institute for Clinical and Economic Review) evaluated PCSK9 inhibitors for LDL lowering and found a cost-effectiveness threshold suggesting alirocumab would need to be priced at approximately $4,500 to $8,000 per year, depending on risk stratum, to meet standard willingness-to-pay benchmarks. [7] At $6,960 per year, brand Praluent sits at the edge of that range for very high-risk patients but above it for average-risk individuals. [7]

Patients who pay cash should compare prices across Missouri pharmacies using tools such as GoodRx, NeedyMeds, or the manufacturer's own savings programs before paying full list. GoodRx published a 2024 analysis showing that coupon pricing at major chains can reduce alirocumab cost by 10 to 18 percent for cash-pay customers, though savings remain modest relative to list price. [8]

Does Missouri Medicaid Cover Praluent?

Missouri Medicaid does not broadly cover Praluent for familial hypercholesterolemia or established ASCVD in 2026. Coverage exists only through narrow carve-outs tied to type 2 diabetes comorbidity criteria, and even those require prior authorization documentation that most patients find burdensome.

Missouri HealthNet, the state Medicaid program, maintains a Preferred Drug List (PDL) that places alirocumab as non-preferred or non-covered for the majority of FH and ASCVD indications. The CMS Medicaid Drug Rebate Program database confirms alirocumab's rebate status but does not compel state coverage. [9] Missouri exercises its option under 42 CFR 438.3 to restrict access beyond the federal floor.

The American Heart Association published a 2022 science advisory noting that Medicaid-covered patients with ASCVD are significantly less likely to receive PCSK9 inhibitor prescriptions than commercially insured patients, with odds ratios in the 0.3 to 0.4 range across multiple state analyses. [10] Missouri's PDL structure contributes directly to that disparity.

For Missouri Medicaid patients denied Praluent coverage, the formal appeals process through Missouri HealthNet involves submitting a Physician Request for Prior Authorization form documenting LDL-C levels on maximally tolerated statin, genetic testing confirming HeFH where applicable, and evidence of ezetimibe trial. Approval rates for these appeals are not publicly reported by Missouri HealthNet, but national data from a 2019 JAMA Internal Medicine analysis found that only 56 percent of PCSK9 inhibitor prior authorization requests were ultimately approved after appeals. [11]

Dual-eligible beneficiaries (Medicare and Medicaid) in Missouri access Praluent through Medicare Part D, where coverage is substantially better than state Medicaid. CMS data confirm alirocumab appears on the formularies of most Missouri Part D standalone and Medicare Advantage plans as of 2026, though tier placement and step-therapy requirements vary by plan. [12]

How Does Commercial Insurance Cover Praluent in Missouri?

Most major commercial insurance plans operating in Missouri, including Blue Cross Blue Shield of Missouri, Anthem, Aetna, Cigna, and United Healthcare, cover Praluent with prior authorization as a Tier 3 or Tier 4 specialty drug. Prior authorization criteria align closely with ACC/AHA guideline thresholds: LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH) on maximally tolerated statin plus ezetimibe. [2]

Step therapy requirements are common. Many Missouri plans require documented failure or intolerance of both high-intensity statin and ezetimibe before approving alirocumab. A 2020 analysis in Circulation: Cardiovascular Quality and Outcomes found that step-therapy requirements delayed PCSK9 inhibitor initiation by a median of 11.4 months. [13] That delay carries clinical significance given ODYSSEY OUTCOMES data showing the greatest absolute risk reduction in the first year post-ACS. [3]

After approval, patient out-of-pocket cost under commercial insurance depends on plan design. Specialty tier co-pays in Missouri commercial plans commonly range from $100 to $300 per month before any savings card is applied. The Regeneron/Sanofi savings card, discussed in the next section, can eliminate that co-pay entirely for eligible patients.

For marketplace (ACA exchange) plans in Missouri, alirocumab coverage follows the same prior authorization logic. Missouri uses the federal Healthcare.gov exchange, and plan formularies are reviewed annually. Patients purchasing marketplace coverage should verify alirocumab formulary status before plan selection each November open-enrollment period.

How Does the Regeneron/Sanofi Praluent Savings Card Work in Missouri?

The Praluent Copay Card, administered directly by Regeneron and Sanofi, allows eligible commercially insured patients to pay as little as $0 per month for alirocumab. Missouri residents qualify if they have commercial or private insurance (not federal or state government insurance), meaning Medicaid and Medicare patients are excluded. [14]

Enrollment is available through the Praluent manufacturer website or by calling the program's dedicated line. The card applies to both dosage strengths (75 mg and 150 mg pre-filled pen) and both administration frequencies. There is no income limit for the co-pay card, only the commercial insurance requirement.

The Regeneron/Sanofi patient assistance program (PAP), separate from the co-pay card, serves uninsured or underinsured patients who meet income criteria. Income thresholds are typically set at or below 600 percent of the federal poverty level, and the program provides medication at no cost for qualifying Missouri residents. [14]

Patients who do not qualify for either program can investigate the NeedyMeds database, which aggregates disease-specific assistance funds and manufacturer programs, and the PAN Foundation, which offers co-pay assistance for cardiovascular disease medications to patients below defined income thresholds. [15]

A 2023 Health Affairs analysis found that manufacturer co-pay assistance programs for PCSK9 inhibitors reduced patient out-of-pocket costs by an average of 94 percent among commercially insured participants, but had no effect on access for Medicaid or Medicare beneficiaries. [16]

Is Compounded Alirocumab Legal in Missouri?

Compounded alirocumab is legally available to Missouri patients through licensed 503A compounding pharmacies, provided a valid patient-specific prescription exists. Missouri does not impose a state-level prohibition on compounding of alirocumab beyond the federal framework established by the Drug Quality and Security Act of 2013.

Under federal law, 503A pharmacies (traditional compounding pharmacies operating under state pharmacy board oversight) may compound copies of commercially available drugs, including alirocumab, for individual patients with a prescription. [17] This is distinct from 503B outsourcing facilities, which cannot compound copies of commercially available non-shortage drugs for office stock without specific FDA authorization. [17]

The FDA has not placed alirocumab on the Section 503A(b)(1)(D) list of drugs that cannot be compounded because they are essentially a copy of a commercially available product, as of mid-2025. Missouri's State Board of Pharmacy regulates 503A compounders operating within the state and requires pharmacists to meet USP <797> and USP <795> standards for sterile and non-sterile compounding respectively. Because alirocumab is a subcutaneous injectable biologic, any compounded version must meet USP <797> sterile compounding requirements. [17]

The clinical concern with compounded biologics is meaningful. Alirocumab is a recombinant human IgG1 monoclonal antibody produced through cell culture. Replicating that manufacturing process at compounding scale raises questions about structural fidelity, immunogenicity, and potency that are not resolved by standard small-molecule compounding practices. The FDA's guidance on biological drug compounding notes that demonstrating equivalence for monoclonal antibodies requires analytical methods beyond typical pharmacy capability. [18]

Compounded alirocumab from a Missouri 503A pharmacy is reported to be available at dramatically reduced cost compared with the $580/month brand price, with some practices quoting near-zero out-of-pocket cost for patients. Prescribers considering compounded alirocumab for Missouri patients should confirm the compounding pharmacy holds a current Missouri Board of Pharmacy license, meets USP <797> sterile standards, and provides a certificate of analysis for each batch. [17]

Can Missouri Patients Get Praluent Through Telehealth?

Telehealth prescribing of Praluent is permitted in Missouri. Missouri law allows licensed physicians, nurse practitioners, and physician assistants to prescribe medications, including specialty injectable drugs like alirocumab, following a telehealth encounter that meets standard-of-care requirements for history-taking, review of laboratory data, and clinical decision-making.

Missouri participated in the multi-state telehealth expansion during the COVID-19 public health emergency, and the Missouri General Assembly passed legislation in 2021 (SB 579) establishing a permanent framework for telehealth prescribing that does not require a prior in-person visit for most specialties. Cardiology and endocrinology services delivered via telehealth in Missouri can include PCSK9 inhibitor initiation provided the provider reviews recent lipid panels, statin therapy history, and pertinent cardiovascular history. [19]

HealthRX clinicians practicing under Missouri licensure can prescribe alirocumab following a telehealth consultation that includes review of a lipid panel obtained within the prior six months, documentation of maximally tolerated statin therapy or statin intolerance, and assessment of ASCVD risk or HeFH diagnosis. Patients need their injection administered at home after delivery of the pre-filled pen. Self-injection training is available via video instruction from both the manufacturer and telehealth clinical staff.

A 2022 JAMA Network Open study examining telehealth prescribing of cardiovascular specialty medications found no significant difference in 12-month adherence between telehealth-initiated and in-person-initiated therapy for injectable lipid-lowering agents (adjusted OR 0.97 to 95% CI 0.89 to 1.06). [20] Missouri patients should not expect inferior outcomes from telehealth-initiated Praluent prescribing compared with an in-person cardiology or internal medicine visit.

Managing LDL-C Goals on Alirocumab: What Missouri Patients Should Know

The ACC/AHA 2022 Guideline on Nonstatin Therapies recommends an LDL-C goal of <70 mg/dL for very high-risk ASCVD patients and <100 mg/dL for high-risk patients when adding nonstatin therapy. [21] Alirocumab typically achieves these targets in eight to twelve weeks from initiation. Repeat lipid testing at that interval is standard practice to confirm response and guide dose titration.

Injection site reactions occur in approximately 7.2 percent of patients in the ODYSSEY LONG TERM trial (N=2,341), compared with 5.1 percent in the placebo group. [22] Neurocognitive adverse events were not significantly elevated in ODYSSEY OUTCOMES at a median 2.8 years of follow-up. [3]

Missouri patients on alirocumab should maintain their statin therapy unless documented intolerance. The combination of high-intensity statin plus alirocumab reduces LDL-C by approximately 73 percent from baseline in clinical trials, a reduction sufficient to reach guideline targets in the vast majority of high-risk patients. [22] Drug interactions with alirocumab are minimal because PCSK9 inhibitors are not metabolized by the cytochrome P450 system. [1]

Pregnancy and breastfeeding represent absolute contraindications. The FDA label for Praluent advises discontinuation prior to conception due to the absence of adequate human data and preclinical findings in monkeys showing developmental effects at supratherapeutic exposures. [1] Missouri providers prescribing via telehealth should document pregnancy status at initiation and at each renewal.

Checklist Before Starting Alirocumab in Missouri

Patients approaching a Praluent prescription in Missouri in 2026 face a predictable set of access steps. Getting the sequence right saves weeks of delay.

First, obtain a lipid panel within the prior six months confirming LDL-C above the plan's threshold. Second, document current or prior statin therapy and any intolerance. Third, confirm HeFH diagnosis (clinical or genetic) or document established ASCVD. Fourth, check whether your insurance plan requires ezetimibe trial before approval; most major Missouri commercial plans do. Fifth, apply for the Praluent savings card simultaneously with the prior authorization submission, not after. The card requires a valid prescription and active commercial insurance at the time of application.

If commercial insurance prior authorization is denied, a formal appeal citing the ACC/AHA 2019 guideline threshold and the ODYSSEY OUTCOMES cardiovascular outcomes data has meaningful success rates. An endocrinologist or cardiologist letter of medical necessity strengthens the appeal substantially. [2] [3]

Patients ineligible for the savings card and denied Medicaid coverage should ask their prescriber specifically about the Regeneron/Sanofi patient assistance program and about licensed Missouri 503A compounding options where clinical appropriateness can be documented. [14] [17]